You are here: Industry Insights > PTC Therapeutics

News List

PTC Therapeutics Initiates Trial to Evaluate Vatiquinone in Friedreich Ataxia americanpharmaceuticalreview
December 15, 2020
PTC Therapeutics announced the initiation of the registration-directed Phase 3 MOVE-FA study evaluating vatiquinone (PTC743) in children and young adults with Friedreich ataxia (FA).
PTC Therapeutics Announces Trial for Huntington's Disease americanpharmaceuticalreview
December 01, 2020
PTC Therapeutics announced the initiation of a Phase 1 clinical trial to evaluate PTC518 in healthy volunteers. PTC518 was identified from PTC's splicing platform and is being developed for the treatment of Huntington's disease (HD).
PTC Therapeutics Announces Initiation of Phase 2/3 Clinical Trial in Australia to Evaluate PTC299 for the Treatment of COVID-19 prnasia
November 16, 2020
PTC Therapeutics, Inc., today announced the initiation of a Phase 2/3 trial called FITE19 to investigate PTC299, a dihydroorotate dehydrogenase (DHODH) inhibitor, as a potential treatment for COVID-19.
PTC Therapeutics Achieves $20M Roche Milestone contractpharma
August 28, 2020
Payment was triggered by the first commercial sale of Evrysdi in the U.S. which was approved by the FDA on August 7 to treat SMA.
PTC Therapeutics Announces FDA Approval of Evrysdi for Spinal Muscular Atrophy americanpharmaceuticalreview
August 13, 2020
PTC Therapeutics announced the U.S. Food and Drug Administration (FDA) has approved Evrysdi™ (risdiplam), the first at-home, orally administered treatment for spinal muscular atrophy (SMA) in adults and children 2 months and older.
PTC Announces the Phase 2/3 Clinical Trial to Evaluate PTC299 for COVID-19 americanpharmaceuticalreview
June 29, 2020
PTC Therapeutics announced the U.S. Food and Drug Administration (FDA) has authorized the initiation of a Phase 2/3 trial to investigate PTC299, a dihydroorotate dehydrogenase (DHODH) inhibitor, as a potential treatment for COVID-19.
PTC Begins Phase II/III Trial of PTC299 in COVID-19 contractpharma
June 18, 2020
PTC299 has a novel dual-mechanism of action that has the potential to address high viral replication and uncontrolled inflammatory response.
PTC Announces Regulatory Update on Risdiplam for Spinal Muscular Atrophy americanpharmaceuticalreview
April 13, 2020
PTC Therapeutics announced the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the New Drug Application (NDA) of risdiplam to August 24, 2020.
PTC Therapeutics to commercialise Akcea’s two rare disease drugs pharmaceutical-technology
August 06, 2018
Ionis Pharmaceuticals affiliate Akcea Therapeutics has signed an agreement with biopharmaceutical company PTC Therapeutics for the commercialisation of its rare disease drugs Tegsedi (inotersen) and Waylivra (volanesorsen) in Latin America.